erlotinib hydrochloride has been researched along with vitamin k 3 in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (vitamin k 3) | Trials (vitamin k 3) | Recent Studies (post-2010) (vitamin k 3) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,316 | 10 | 504 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | vitamin k 3 (IC50) |
|---|---|---|---|
| perilipin-5 | Homo sapiens (human) | 9.468 | |
| perilipin-1 | Homo sapiens (human) | 7.895 | |
| 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a | Homo sapiens (human) | 8.6815 | |
| Aldehyde oxidase 1 | Mus musculus (house mouse) | 0.15 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 7.96 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 7.96 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 0.8925 | |
| Protein kinase C alpha type | Homo sapiens (human) | 2.2 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 3.02 | |
| Protein-glutamine gamma-glutamyltransferase 2 | Homo sapiens (human) | 2.2 | |
| M-phase inducer phosphatase 1 | Homo sapiens (human) | 4.55 | |
| M-phase inducer phosphatase 2 | Homo sapiens (human) | 3.16 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 2.2 | |
| Aldehyde oxidase 1 | Oryctolagus cuniculus (rabbit) | 2 | |
| Aldehyde oxidase | Homo sapiens (human) | 0.2 | |
| Receptor-type tyrosine-protein phosphatase eta | Homo sapiens (human) | 2.2 | |
| Thiosulfate sulfurtransferase | Homo sapiens (human) | 1 | |
| Receptor protein-tyrosine kinase | Homo sapiens (human) | 2.2 | |
| 60 kDa chaperonin | Escherichia coli | 5.75 | |
| Aldehyde oxidase 1 | Macaca fascicularis (crab-eating macaque) | 0.11 | |
| 10 kDa chaperonin | Escherichia coli | 5.75 | |
| Aldehyde oxidase 1 | Rattus norvegicus (Norway rat) | 0.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, T; Perez-Soler, R | 1 |
| Li, T; Ling, YH; Perez-Soler, R; Zou, Y | 1 |
1 review(s) available for erlotinib hydrochloride and vitamin k 3
| Article | Year |
|---|---|
Skin toxicities associated with epidermal growth factor receptor inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Head and Neck Neoplasms; Humans; Mice; Pancreatic Neoplasms; Patient Education as Topic; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Vitamin K 3 | 2009 |
1 other study(ies) available for erlotinib hydrochloride and vitamin k 3
| Article | Year |
|---|---|
The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Growth Processes; Cetuximab; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Humans; Keratinocytes; Mice; Mice, Inbred ICR; Phosphorylation; Protein Tyrosine Phosphatases; Quinazolines; Reactive Oxygen Species; Skin; Vitamin K 3 | 2011 |